PeptiDream Inc. Logo

PeptiDream Inc.

4587.T

(1.5)
Stock Price

2.631,00 JPY

25.41% ROA

49.8% ROE

16.45x PER

Market Cap.

356.820.104.363,00 JPY

35.61% DER

0% Yield

39.14% NPM

PeptiDream Inc. Stock Analysis

PeptiDream Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PeptiDream Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (26.67%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a reasonable amount of debt compared to its ownership (63%), suggesting a balanced financial position and a moderate level of risk.

4 Buffet Intrinsic Value

The company's stock seems undervalued (5.905) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (5.24x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

PeptiDream Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PeptiDream Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

PeptiDream Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PeptiDream Inc. Revenue
Year Revenue Growth
2011 269.004.000
2012 678.269.000 60.34%
2013 818.901.000 17.17%
2014 2.474.499.000 66.91%
2015 4.327.878.000 42.82%
2016 4.895.747.000 11.6%
2017 6.426.891.000 23.82%
2018 7.216.622.000 10.94%
2019 2.074.674.000 -247.84%
2020 11.677.253.000 82.23%
2021 9.365.964.000 -24.68%
2022 26.852.430.000 65.12%
2023 52.471.604.000 48.82%
2023 28.712.194.000 -82.75%
2024 127.633.836.000 77.5%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PeptiDream Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 0
2012 0 0%
2013 0 0%
2014 88.549.000 100%
2015 228.212.000 61.2%
2016 362.681.000 37.08%
2017 921.343.000 60.64%
2018 0 0%
2019 1.786.534.000 100%
2020 1.460.973.000 -22.28%
2021 1.654.429.000 11.69%
2022 2.915.118.000 43.25%
2023 3.013.124.000 3.25%
2023 3.155.366.000 4.51%
2024 3.124.544.000 -0.99%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PeptiDream Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 1.354.534.000 100%
2022 6.220.618.000 78.23%
2023 7.072.980.000 12.05%
2023 7.256.195.000 2.52%
2024 7.693.592.000 5.69%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PeptiDream Inc. EBITDA
Year EBITDA Growth
2011 23.381.000
2012 213.176.000 89.03%
2013 275.104.000 22.51%
2014 1.497.231.000 81.63%
2015 2.697.580.000 44.5%
2016 2.685.576.000 -0.45%
2017 3.427.079.000 21.64%
2018 4.101.262.000 16.44%
2019 -1.261.798.000 425.03%
2020 8.518.591.000 114.81%
2021 5.001.974.000 -70.3%
2022 10.939.347.000 54.28%
2023 33.802.380.000 67.64%
2023 9.608.461.000 -251.8%
2024 105.201.344.000 90.87%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PeptiDream Inc. Gross Profit
Year Gross Profit Growth
2011 101.582.000
2012 410.690.000 75.27%
2013 504.138.000 18.54%
2014 1.752.860.000 71.24%
2015 3.241.587.000 45.93%
2016 3.535.946.000 8.32%
2017 4.648.265.000 23.93%
2018 5.565.368.000 16.48%
2019 661.062.000 -741.88%
2020 9.529.349.000 93.06%
2021 7.007.951.000 -35.98%
2022 18.113.488.000 61.31%
2023 41.075.524.000 55.9%
2023 16.862.543.000 -143.59%
2024 113.928.748.000 85.2%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PeptiDream Inc. Net Profit
Year Net Profit Growth
2011 9.971.000
2012 137.180.000 92.73%
2013 148.512.000 7.63%
2014 1.004.164.000 85.21%
2015 1.581.288.000 36.5%
2016 1.890.750.000 16.37%
2017 2.335.216.000 19.03%
2018 2.770.141.000 15.7%
2019 -976.928.000 383.56%
2020 4.448.357.000 121.96%
2021 3.606.407.000 -23.35%
2022 7.554.358.000 52.26%
2023 17.081.784.000 55.78%
2023 3.035.832.000 -462.67%
2024 75.071.380.000 95.96%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PeptiDream Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 0
2012 2 100%
2013 1 0%
2014 9 88.89%
2015 14 35.71%
2016 17 12.5%
2017 19 15.79%
2018 22 13.64%
2019 -8 414.29%
2020 35 120%
2021 28 -29.63%
2022 58 53.45%
2023 132 55.73%
2023 23 -469.57%
2024 579 96.03%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PeptiDream Inc. Free Cashflow
Year Free Cashflow Growth
2011 -207.250.000
2012 121.941.000 269.96%
2013 -969.000 12684.21%
2014 147.867.000 100.66%
2015 -435.598.000 133.95%
2016 -403.823.000 -7.87%
2017 -1.448.995.000 72.13%
2018 4.285.919.000 133.81%
2019 103.731.000 -4031.76%
2020 1.146.473.000 90.95%
2021 5.440.030.000 78.93%
2022 -4.058.345.000 234.05%
2023 11.014.007.000 136.85%
2023 133.616.000 -8143.03%
2024 -1.194.568.999 111.19%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PeptiDream Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 -150.484.000
2012 234.566.000 164.15%
2013 72.174.000 -225%
2014 1.386.143.000 94.79%
2015 1.533.057.000 9.58%
2016 1.530.776.000 -0.15%
2017 1.022.716.000 -49.68%
2018 4.480.938.000 77.18%
2019 241.982.000 -1751.77%
2020 1.732.733.000 86.03%
2021 6.654.708.000 73.96%
2022 -82.929.000 8124.58%
2023 12.382.969.000 100.67%
2023 417.108.000 -2868.77%
2024 -736.851.999 156.61%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PeptiDream Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 56.766.000
2012 112.625.000 49.6%
2013 73.143.000 -53.98%
2014 1.238.276.000 94.09%
2015 1.968.655.000 37.1%
2016 1.934.599.000 -1.76%
2017 2.471.711.000 21.73%
2018 195.019.000 -1167.42%
2019 138.251.000 -41.06%
2020 586.260.000 76.42%
2021 1.214.678.000 51.74%
2022 3.975.416.000 69.45%
2023 1.368.962.000 -190.4%
2023 283.492.000 -382.89%
2024 457.717.000 38.06%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PeptiDream Inc. Equity
Year Equity Growth
2011 327.279.000
2012 5.696.241.000 94.25%
2013 5.863.203.000 2.85%
2014 6.912.431.000 15.18%
2015 10.242.755.000 32.51%
2016 12.180.801.000 15.91%
2017 14.708.715.000 17.19%
2018 17.449.053.000 15.7%
2019 16.978.288.000 -2.77%
2020 21.217.003.000 19.98%
2021 24.998.595.000 15.13%
2022 32.041.465.000 21.98%
2023 37.461.364.000 14.47%
2023 38.012.491.000 1.45%
2024 58.770.634.000 35.32%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PeptiDream Inc. Assets
Year Assets Growth
2011 405.869.000
2012 5.926.153.000 93.15%
2013 5.999.273.000 1.22%
2014 7.738.442.000 22.47%
2015 11.956.402.000 35.28%
2016 13.628.452.000 12.27%
2017 16.502.264.000 17.41%
2018 20.040.205.000 17.65%
2019 17.817.340.000 -12.48%
2020 26.266.729.000 32.17%
2021 26.619.168.000 1.32%
2022 63.865.200.000 58.32%
2023 66.103.857.000 3.39%
2023 67.126.795.000 1.52%
2024 95.881.241.000 29.99%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PeptiDream Inc. Liabilities
Year Liabilities Growth
2011 78.590.000
2012 229.912.000 65.82%
2013 136.070.000 -68.97%
2014 826.011.000 83.53%
2015 1.713.647.000 51.8%
2016 1.447.651.000 -18.37%
2017 1.793.549.000 19.29%
2018 2.591.152.000 30.78%
2019 839.052.000 -208.82%
2020 5.049.726.000 83.38%
2021 1.620.573.000 -211.6%
2022 31.823.735.000 94.91%
2023 28.642.493.000 -11.11%
2023 29.114.299.000 1.62%
2024 37.110.605.000 21.55%

PeptiDream Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
427.59
Net Income per Share
167.35
Price to Earning Ratio
16.45x
Price To Sales Ratio
6.44x
POCF Ratio
374.2
PFCF Ratio
-435.57
Price to Book Ratio
6.07
EV to Sales
6.36
EV Over EBITDA
10.09
EV to Operating CashFlow
369.44
EV to FreeCashFlow
-430.02
Earnings Yield
0.06
FreeCashFlow Yield
-0
Market Cap
356,82 Bil.
Enterprise Value
352,27 Bil.
Graham Number
1306.67
Graham NetNet
110.74

Income Statement Metrics

Net Income per Share
167.35
Income Quality
0.04
ROE
0.5
Return On Assets
0.23
Return On Capital Employed
0.42
Net Income per EBT
0.71
EBT Per Ebit
0.94
Ebit per Revenue
0.59
Effective Tax Rate
0.28

Margins

Sales, General, & Administrative to Revenue
0.14
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.78
Operating Profit Margin
0.59
Pretax Profit Margin
0.55
Net Profit Margin
0.39

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
7.36
Free CashFlow per Share
-6.32
Capex to Operating CashFlow
1.86
Capex to Revenue
0.03
Capex to Depreciation
0.75
Return on Invested Capital
0.29
Return on Tangible Assets
0.25
Days Sales Outstanding
215.9
Days Payables Outstanding
104.29
Days of Inventory on Hand
83.46
Receivables Turnover
1.69
Payables Turnover
3.5
Inventory Turnover
4.37
Capex per Share
13.68

Balance Sheet

Cash per Share
196,62
Book Value per Share
453,44
Tangible Book Value per Share
372.34
Shareholders Equity per Share
453.44
Interest Debt per Share
178.94
Debt to Equity
0.36
Debt to Assets
0.22
Net Debt to EBITDA
-0.13
Current Ratio
3.39
Tangible Asset Value
48,26 Bil.
Net Current Asset Value
24,67 Bil.
Invested Capital
71330263000
Working Capital
43,53 Bil.
Intangibles to Total Assets
0.11
Average Receivables
18,75 Bil.
Average Payables
3,25 Bil.
Average Inventory
2764158500
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PeptiDream Inc. Dividends
Year Dividends Growth

PeptiDream Inc. Profile

About PeptiDream Inc.

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.

CEO
Dr. Patrick Crawford Reid Ph.
Employee
745
Address
3-25-23 Tonomachi
Kawasaki, 210-0821

PeptiDream Inc. Executives & BODs

PeptiDream Inc. Executives & BODs
# Name Age
1 Dr. Patrick Crawford Reid Ph.D.
President, Chief Executive Officer & Representative Director
70
2 Yuko Okimoto
IR & Public Relations Director
70
3 Mr. Christian Cunningham Ph.D.
Chief Scientific Officer
70
4 Dr. Keiichi Masuya Ph.D.
Chief Operating Officer, Executive Vice President & Director
70
5 Masato Murakami M.B.A., M.D., Ph.D.
Chief Medical Officer
70
6 Dr. Kiyofumi Kaneshiro Ph.D.
Chief Financial Officer, Executive Vice President & Director
70

PeptiDream Inc. Competitors

M3, Inc. Logo
M3, Inc.

2413.T

(3.2)
Shionogi & Co., Ltd. Logo
Shionogi & Co., Ltd.

4507.T

(3.2)
Takara Bio Inc. Logo
Takara Bio Inc.

4974.T

(3.2)